2 completed, 2 recruiting, 1 active not recruiting, 1 not yet recruiting. 3 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Not yet recruiting 1 |
| Phase 1 | 2 | Recruiting 2 |
| Phase 3 | 1 | Completed 1 |
Follow Biliary Tract Cancers: new trials by email Literature Review of Biliary Tract Cancers trials Research Report on Biliary Tract Cancers
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer Daraxonrasib - Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc) | Phase 2 | Not yet recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 55 | 2026-11-01 | 2026-08-28 |
| Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer Anlotinib + Cadonilimab, PULSAR - Previously Treated, Advanced, Biliary Tract Cancers | Phase 2 | Active not recruiting | West China Hospital | 26 | 2026-06-03 | 2026-06-09 |
| Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC) mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)], Durvalumab, Tremelimumab - Biliary Tract Cancers | Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 25 | 2025-05-27 | 2026-05-08 |
| Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 ABBV-400, Itraconazole (ITZ), Bevacizumab - Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma | Phase 1 | Recruiting | AbbVie | 325 | 2023-11-09 | 2026-10-14 |
| A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC) durvalumab - Biliary Tract Cancers | Phase 3 | Completed | AstraZeneca | 116 | 2023-07-21 | 2025-04-22 |
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) Pembrolizumab, Lenvatinib - Advanced Solid Tumors, Triple Negative Breast Cancer | Phase 2 | Completed | Merck Sharp & Dohme LLC | 611 | 2019-02-12 | 2026-05-04 |
Biliary Tract Neoplasms (6) · Carcinoma (2) · Triple Negative Breast Neoplasms (2) · Carcinoma, Hepatocellular (1) · Cholangiocarcinoma (1) · Cirrhosis, Familial, with Pulmonary Hypertension (1) · Colorectal Neoplasms (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Esophageal Squamous Cell Carcinoma (1) · Gallbladder Neoplasms (1) · Gastrointestinal Neoplasms (1) · Glioblastoma (1) · Liver Neoplasms (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1)
Biliary Tract Diseases (6) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Neoplasms (6) · Neoplasms by Site (6) · Neoplasms by Histologic Type (4) · Neoplasms, Glandular and Epithelial (4) · Gastrointestinal Diseases (3) · Adenocarcinoma (2) · Breast Diseases (2) · Breast Neoplasms (2) · Gastrointestinal Neoplasms (2) · Liver Diseases (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2)
durvalumab (2) · Bevacizumab (1) · DEAE-Dextran (1) · Itraconazole (1) · Peptides (1) · anlotinib (1) · lenvatinib (1) · pembrolizumab (1) · poly ICLC (1) · tremelimumab (1)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · AbbVie (1) · AstraZeneca (1) · Merck Sharp & Dohme LLC (1) · West China Hospital (1)
United States (4) · Australia (2) · China (2) · Israel (2) · South Korea (2) · Spain (2) · Taiwan (2) · Argentina (1) · Canada (1) · Chile (1) · Colombia (1) · France (1) · Germany (1) · Italy (1) · Japan (1)
Marina Baretti, MD (1) · Nilo Azad, MD (1)
PMID 38718741, PMID 39031824, PMID 40808295, PMID 41747221, PMID 41763955
2018 (1), 2023 (1)